Phase 3 Systemic Clinical Trials
41 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 41 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled233 locationsNCT06617325
Recruiting
Phase 3
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AstraZeneca245 enrolled103 locationsNCT07430306
Recruiting
Phase 3
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled13 locationsNCT07332481
Recruiting
Phase 3
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Lupus Erythematosus, SystemicNephritis, Lupus
Viatris Innovation GmbH300 enrolled14 locationsNCT07201129
Recruiting
Phase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
AstraZeneca100 enrolled99 locationsNCT05835310
Recruiting
Phase 3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled222 locationsNCT07438496
Recruiting
Phase 3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim400 enrolled158 locationsNCT06806592
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled143 locationsNCT06133972
Recruiting
Phase 2Phase 3
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
SclerodermaSystemic Sclerosis
University Hospital, Bordeaux90 enrolled11 locationsNCT05098704
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company58 enrolled55 locationsNCT04088396
Recruiting
Phase 2Phase 3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Indolent Systemic MastocytosisSmoldering Systemic Mastocytosis
Blueprint Medicines Corporation534 enrolled71 locationsNCT04910685
Recruiting
Phase 2Phase 3
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Systemic Lupus ErythematosusImmune Thrombocytopenia
Chinese SLE Treatment And Research Group164 enrolled1 locationNCT07657793
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company92 enrolled56 locationsNCT07335562
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
Interstitial Lung Disease With Systemic Sclerosis
University Hospital, Tours102 enrolled1 locationNCT06549231
Recruiting
Phase 3
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Beijing Mabworks Biotech Co., Ltd.316 enrolled1 locationNCT07405970
Recruiting
Phase 3
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Interstitial Lung DiseaseSystemic Sclerosis
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland86 enrolled1 locationNCT06297096
Recruiting
Phase 3
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
Heart FailureSystemic Inflammation
Novo Nordisk A/S680 enrolled240 locationsNCT06200207
Recruiting
Phase 3
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 3
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Viatris Innovation GmbH420 enrolled216 locationsNCT05648500
Recruiting
Phase 3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AbbVie1,000 enrolled369 locationsNCT05843643